[Gefitinib molecular target therapy for Chinese patients with non-small cell lung cancer].
BACKGROUND
To explore the experience of gefitinib molecular target therapy for Chinese patients with non-small cell lung cancer (NSCLC).


METHODS
The unpublished data of gefitinib for advanced NSCLC in 7 hospitals were collected. The detailed data from Guangdong Provincial People's Hospital were analyzed.


RESULTS
A total of 282 patients with advanced NSCLC was treated with gefitinib from July 2001 to December 2003. Response rate was 22.2%-47.7%, disease control rate 62.6%-81.8%. No severe side effects were surveyed.


CONCLUSIONS
Gefitinib can be used safely and effectively in Chinese patients with advanced NSCLC.
The Lung Cancer Research Institute and Cancer Center, Guangdong Provincial People's Hospital, Guangzhou, Guangdong 510080, P.R.China.
Yilong
Y
Wu
Xuening
X
Yang
Jinji
J
Yang
Yujuan
Y
Huang